Back to top
more

Baxter International (BAX)

(Real Time Quote from BATS)

$35.20 USD

35.20
1,464,509

-0.15 (-0.42%)

Updated Jul 22, 2024 01:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.

Veeva Systems (VEEV) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Veeva Systems (VEEV) fiscal fourth-quarter results are likely to reflect robust product portfolio and higher revenues.

Why Earnings Season Could Be Great for Baxter (BAX)

by Zacks Equity Research

Baxter (BAX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

DENTSPLY SIRONA (XRAY) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) fourth-quarter performance to reflect better-than-expected performance at Technology & Equipment and growth in emerging markets.

What's in Store for Fulgent Genetics (FLGT) Q4 Earnings?

by Zacks Equity Research

Fulgent Genetics' (FLGT) fourth-quarter 2019 earnings are likely to reflect top-line growth and elevated test volumes.

Baxter's Latest Acquisition to Boost Advanced Surgery Arm

by Zacks Equity Research

Baxter's (BAX) Advanced Surgery arm boasts of a wide spectrum of products.

Baxter (BAX) and COSMED Receive FDA Clearance for Q-NRG+

by Zacks Equity Research

The latest FDA clearance is likely to boost Baxter's (BAX) Clinical Nutrition segment.

Medical Products' Jan 30 Earnings Roster: TMO, EW & More

by Zacks Equity Research

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

Baxter (BAX) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Higher revenues, solid product portfolio and strong performance across six global business units are likely to have benefited Baxter's (BAX) Q4 earnings.

What's in Store for Varian Medical (VAR) in Q1 Earnings?

by Zacks Equity Research

Demand for Eclipse and TrueBeam is expected to have driven Varian's (VAR) Oncology revenues in fiscal Q1.

Stryker (SYK) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Solid segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine are likely to have contributed to Stryker's (SYK) Q4 earnings.

PerkinElmer (PKI) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Top-line growth and robust performance at Diagnostics segment are likely to have aided PerkinElmer's (PKI) Q4 earnings. However, forex is likely to have remained a woe.

What's in the Cards for Intuitive Surgical (ISRG) Q4 Earnings?

by Zacks Equity Research

Better-than-expected performance at Instruments & Accessories segment and da Vince procedure growth are likely to have benefited Intuitive Surgical's (ISRG) Q4 earnings.

Baxter Posts Upbeat Q4 Preliminary Results, Issues Guidance

by Zacks Equity Research

Higher revenues, growth in all geographic segments and six business units benefit Baxter's (BAX) Q4 preliminary operating results.

Baxter (BAX) Misses Q3 Revenue Estimates, Issues Guidance

by Zacks Equity Research

Higher revenues, growth in all geographic segments and strong fourth-quarter 2019 revenue outlook benefit Baxter's (BAX) Q3 preliminary operating results. However, gross margin contraction remains a woe.

Medical Products' Oct 24 Earnings Roster: BAX, CERN & More

by Zacks Equity Research

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

Trina Mukherjee headshot

Medical Products Industry Outlook: Prospects Seem Promising

by Trina Mukherjee

Growth prospects look bright for the Zacks Medical Products industry, thanks to AI, Medical Mechatronics and Robotics and rampant M&As.

What's in the Offing for Baxter's (BAX) Earnings in Q3?

by Zacks Equity Research

Baxter's (BAX) Q3 earnings is likely to have benefited from better-than-expected performance at Acute Therapies segment, solid product portfolio and anticipated rise in revenues.

Baxter International (BAX) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HRC or BAX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

HRC vs. BAX: Which Stock Is the Better Value Option?

Stryker Gains From Flagship Mako and Broad Product Spectrum

by Zacks Equity Research

Stryker's (SYK) broad product spectrum cushions the company from any significant sales shortfall.

Abbott (ABT) Gets FDA Nod for New Troponin-I Blood Test

by Zacks Equity Research

The regulatory go-ahead for Abbott's (ABT) ARCHITECT STAT High Sensitivity Troponin-I blood test is a major stride forward in its commitment for detecting patients suspected of having a heart attack.

Haemonetics Grows on Strong Plasma, Hemostasis Management

by Zacks Equity Research

Haemonetics (HAE) is gaining traction from a steady progress in Plasma franchise.

Here's Why You Should Hold on to Wright Medical (WMGI) Stock

by Zacks Equity Research

Strong international footprint, solid prospects in the global orthopedic space and an enhanced product pipeline bode well for Wright Medical (WMGI). However, adverse forex mars prospects.

Illumina (ILMN) Gains on Product Pipeline, Global Footprint

by Zacks Equity Research

Illumina (ILMN) pins high hopes on almost a dozen new drugs unveiled with a predictive biomarker (nine of which are already approved for oncology indications).

Medtronic's MiniMed 670G Shows Favorable Outcome in Europe

by Zacks Equity Research

Medtronic's (MDT) MiniMed 670G system boasts a special feature of SmartGuard Auto Mode that improves Time in Range.